3:22 PM
 | 
Nov 06, 2018
 |  BC Extra  |  Clinical News

Aveo RCC compound trends toward detrimental survival effect, again

Despite announcing plans to submit an NDA to FDA for its renal cell carcinoma compound in about six months, Aveo Pharmaceuticals Inc. (NASDAQ:AVEO) lost $0.51 (20%) to $2.03 on Tuesday after reporting preliminary data late Monday that showed no overall survival benefit for Fotivda tivozanib as a third-line treatment vs. Nexavar sorafenib in the Phase III TIVO-3 trial (HR=1.06, p=0.69). The company designed TIVO-3 to address a 2013 complete response letter for Fotivda in which FDA...

Read the full 356 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >